GlassScriptPhysician profile
Katelyn Lyne
NPI 1588258768
$5,035.93
in general payments reported to CMS, 2019-2025
32 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $1,075 · 2023: $1,685 · 2024: $819 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,546.18 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $633.67 | 2021-2025 | |
| Amgen INC. | $520.68 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $449.61 | 2021-2025 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.11 | 2021-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $321.25 | 2022-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $236.59 | 2022-2024 | Xarelto |
| Vital Connect, INC | $194.86 | 2023 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $193.97 | 2022-2025 | Verquvo, Capvaxive |
| Scpharmaceuticals INC. | $193.86 | 2023-2025 | |
| Pfizer INC. | $192.80 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.57 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $121.83 | 2022-2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $120.05 | 2022-2024 | Evkeeza |
| Novo Nordisk INC | $108.49 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $106.37 | 2021-2023 | Optimizer |
| Medicomp INC | $90.38 | 2022-2023 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $80.25 | 2022-2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $77.21 | 2022-2024 | Livalo |
| Kiniksa Pharmaceuticals International, Plc | $65.32 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $58.34 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $39.36 | 2022 | |
| Lilly USA, LLC | $36.16 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $32.37 | 2025 | Attruby |
| Cardiac Dimensions, INC. | $28.18 | 2025 | |
| Siemens Medical Solutions USA, INC. | $25.35 | 2023 | Artis Icono Floor |
| Lantheus Medical Imaging, INC. | $23.29 | 2023 | Definity |
| Atricure, INC. | $22.78 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $21.68 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $19.44 | 2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $18.23 | 2024 | |
| Baxter Healthcare | $15.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Lyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.